

## Supplementary data


**Supplementary Table 1: Inclusion and Exclusion criteria:**

<b>Inclusion criteria</b>
Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
Type 2 diabetes
Male or female $\geq 18$ years of age
HbA <sub>1c</sub> 7.0–9.0% (53–75 mmol/mol) (both inclusive)
Treatment with daily GLP-1RA at maximum dose according to local label (i.e. 1.8 mg once-daily liraglutide or 10 microgram twice-daily exenatide) or documented maximum tolerated dose (i.e. 1.2 mg OD liraglutide or 5 microgram BID exenatide) in combination with a stable daily dose of metformin ( $\geq 1500$ mg or documented maximum tolerated dose) $\pm$ stable daily dose of pioglitazone ( $\geq 30$ mg) $\pm$ stable daily dose of sulfonylurea ( $\geq$ half of the max approved dose according to local label) $\geq 90$ days prior to screening visit.
Body mass index $\leq 40$ kg/m <sup>2</sup>
Able and willing to adhere to the protocol including performing self-monitored plasma glucose profiles, to keep a trial diary and to use pre-filled pen device
<b>Exclusion criteria</b>
Known or suspected hypersensitivity to trial product(s) or related products
Previous participation in this trial. Participation is defined as randomization
Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)
Receipt of any investigational medicinal product within 30 days prior to screening visit (Visit 1)
Use of any drug (except metformin, pioglitazone, sulfonylurea and GLP-1RA) which in the investigator's opinion could interfere with the blood glucose level (e.g. systemic corticosteroids).
Treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the investigator)
Impaired liver function, defined as alanine aminotransferase (ALAT) $\geq 2.5$ times upper normal range (UNR)
Impaired renal function defined as serum-creatinine $\geq 133$ $\mu$ mol/L (1.5 mg/dL) for males and $\geq 125$ $\mu$ mol/L (1.4 mg/dL) for females, or as allowed according to local contraindications for metformin
Screening calcitonin $\geq 50$ ng/L
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
Cardiovascular disorders defined as; congestive heart failure (New York Heart Association (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to Visit 1 and/or planned coronary, carotid or peripheral artery revascularisation procedures
Severe uncontrolled treated or untreated hypertension (systolic blood pressure $\geq 180$ mm Hg or diastolic blood pressure $\geq 100$ mm Hg)
Proliferative retinopathy requiring acute treatment or maculopathy (macular edema) according to the investigator's opinion
Subjects with a clinical significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the type 2 diabetes), neurological, genitourinary or haematological system that in the opinion of the Investigator, may confound the results of the trial or pose additional risk in administering trial product
Mental incapacity, unwillingness or language barrier precluding adequate understanding of the trial procedures or cooperation with the trial personnel
Known or suspected abuse of prescription drugs, alcohol or illicit substances
History of chronic pancreatitis or idiopathic acute pancreatitis
Suffer from a life threatening disease including malignant neoplasms and medical history of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer)

**Supplementary Table 2: Titration algorithm**

Fasting plasma glucose		Dose adjustment Dose steps
mmol/L	mg/dL	
<4.0	<72	-2
4.0–5.0	72–90	0
>5.0	>90	+2

**Supplementary Figure 1: Patient disposition.** FAS, full analysis set; GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; SAS, safety analysis set.



**Supplementary Table 3: Hypoglycemia**

	IDegLira <i>n</i> = 291			Unchanged GLP-1RA <i>n</i> = 145			Estimated rate ratio [95% CI]
	N (%)	Events	Rate	N (%)	Events	Rate	
Severe	1 (0.3)	1	0.007	0 (0)	0	0	N/A
Confirmed	93 (32)	397	2.82	4 (2.8)	8	0.12	25.36 [10.6; 60.5], <i>p</i> < 0.001
Nocturnal confirmed	32 (11)	64	0.45	1 (0.7)	1	0.015	32.82 [4.13; 261.04], <i>p</i> < 0.001

N, number of subjects with  $\geq 1$  event; %, percentage of subjects; rate, unadjusted event rate (episodes per patient-year of exposure). Data are based on the SAS. Estimated rate ratio based on FAS. FAS, full analysis set; GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; PYE, patient years of exposure; SAS, safety analysis set.

**Supplementary Table 4: Hypoglycemia by pre-trial oral anti-diabetic drugs**

	IDegLira + met ± pio n = 223			Unchanged GLP-1RA + met ± pio n = 111			IDegLira + met + SU ± pio n = 68			Unchanged GLP-1RA + met + SU ± pio n = 34		
	N (%)	Events	Rate	N (%)	Events	Rate	N (%)	Events	Rate	N (%)	Events	Rate
Severe	1 (0.4)	1	0.009	0 (0)	0	0	0 (0)	0	0	0 (0)	0	0
Confirmed	62 (28)	189	1.75	0 (0)	0	0	31 (46)	208	6.34	4 (12)	8	0.51

N, number of subjects with ≥1 event; %, percentage of subjects; rate, unadjusted event rate (episodes per patient-year of exposure). Data are based on the SAS. Met, metformin, GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; pio, pioglitazone; PYE, patient years of exposure; SAS; safety analysis set; SU, sulfonylurea.

**Supplementary Table 5: Lipase and amylase by treatment week**

	IDegLira n = 290	Unchanged GLP-1RA n = 145
<b>Lipase, U/L</b>		
Week 0	61.9 (44.3) [17.0; 388.0]	57.3 (37.4) [17.0; 335.0]
Week 12	68.0 (55.6) [14.0; 438.0]	60.8 (39.7) [18.0; 286.0]
Week 26	60.9 (40.1) [13.0; 418.0]	55.5 (39.0) [17.0 429.0]
<b>Amylase, U/L</b>		
Week 0	63.9 (31.1) [13.0; 256.0]	62.2 (31.6) [11.0; 225.0]
Week 12	72.3 (37.7) [20.0; 291.0]	63.3 (31.2) [20.0; 201.0]
Week 26	70.1 (36.8) [23.0; 241.0]	61.2 (26.3) [13.0; 176.0]

Values are mean (standard deviation) [min; max range]. N, number of subjects. Data are based on the SAS with LOCF. Met, metformin, GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; LOCF, last observation carried forward; SAS; safety analysis set.

**Supplementary Table 6: Patient-reported outcomes**

Score	IDegLira (n = 291) Observed score at EOT	Unchanged GLP-1RA (n = 146) Observed score at EOT	IDegLira (n = 290) Observed change from baseline	Unchanged GLP-1RA (n = 146) Observed change from baseline	Estimated treatment contrast [95% CI] ANCOVA analysis IDegLira – GLP-1RA
<b>TRIM-D</b>					
Total score	82.3 ± 11.9	78.1 ± 13.9	8.7 ± 12.0	3.1 ± 12.2	5.0 [2.9, 7.2]; p < 0.001
Treatment burden	81.2 ± 15.9	76.6 ± 18.0	10.8 ± 18.8	5.7 ± 19.3	5.0 [1.9; 8.0]; p = 0.002
Daily life	84.5 ± 16.6	81.7 ± 18.7	6.3 ± 18.4	0.8 ± 18.2	3.7 [0.5; 6.8]; p = 0.022
Diabetes management	72.0 ± 18.5	67.2 ± 20.2	10.9 ± 21.3	4.1 ± 19.8	5.7 [2.2; 9.2]; p = 0.002

Compliance	87.2 ± 14.0	84.4 ± 16.9	8.9 ± 17.3	4.3 ± 15.9	3.5 [0.8; 6.2]; <i>p</i> = 0.010
Psychological health	85.9 ± 14.8	80.5 ± 18.4	7.3 ± 14.7	1.4 ± 16.5	5.4 [2.7; 8.1]; <i>p</i> < 0.001
<b>DTSQs</b>					
Treatment satisfaction total score	32.5 ± 4.2	30.7 ± 5.9	3.1 ± 5.6	1.1 ± 5.0	2.0 [1.1, 2.8]; <i>p</i> < 0.001
Hyperglycemia	1.5 ± 1.6	2.5 ± 2.0	-1.8 ± 2.1	-0.6 ± 1.9	-1.0 [-1.4, -0.7]; <i>p</i> < 0.001
Hypoglycemia	1.1 ± 1.5	0.7 ± 1.4	0.2 ± 1.7	-0.1 ± 1.5	0.4 [0.1, 0.6]; <i>p</i> = 0.006

Data are observed patient-reported outcome scores at 26 weeks, changes from baseline (LOCF), and estimated treatment contrast. Data are mean ± standard deviation unless otherwise indicated. TRIM-D: higher score indicates a better health state. DTSQs: higher scores indicate higher satisfaction; DTSQ hyperglycemia and hypoglycemia: higher scores indicate higher perceived frequency.

ANCOVA, analysis of covariance; CI, confidence interval; DTSQs, diabetes treatment satisfaction questionnaire status; EOT, end-of-trial; GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; LOCF, last observation carried forward; TRIM-D, treatment-related impact measure–diabetes.